伊立替康联合顺铂治疗晚期食管癌疗效观察  

CLINICAL OBSERVATION ON THE IRINOTECAN PLUS CISPLATIN FOR ADVANCED ESOPHAGEAL CANCER

作　　者：陈萍[1] 李晓[1] 卢进[1] 

机构地区：[1]四川省肿瘤医院,成都610041

出　　处：《现代预防医学》2009年第14期2771-2772,共2页Modern Preventive Medicine

摘　　要：[目的]评价伊立替康(CPT-11)联合顺铂(DDP)治疗晚期食管癌的疗效及不良反应。[方法]17例患者均经病理学或细胞学确诊为晚期食管癌,全部病例均有客观评价指标。采用CPT-1160mg/m2,静脉滴注,d1、8;DDP30mg/m2,静脉滴注,d1、8;28d为一周期,连续用2周期后评价疗效及不良反应。[结果]17例均完2个周期化疗,共接受38个周期化疗,全部病例均可评价疗效及不良反应。无完全缓解(CR)病例,部分缓解(PR)7例(41.2%),稳定(NC)2例(11.8%),进展(PD)8例(47.1%),有效率为41.2%;中位生存时间为(MST)9.1个月。不良反应主要是骨髓抑制,恶心、呕吐,腹泻,III-IV级粒细胞减少,血小板减少,恶心、呕吐,腹泻的发生率分别为17.6%,11.8%,23.5%,11.8%。[结论]CPT-11联合DDP治疗晚期食管癌有确切疗效,不良反应轻,耐受性好,可作为复发或治疗失败的晚期食管癌治疗的备选方案之一。[Objective]To evaluate the efficaey and adverse events of irinotecan （CPT-11） combined with eisplatin （DDP） in the treatment of patients with advanced esophageal cancer. [ Methods] A total of 17 patients diagnosed by with pathology and cytology, were recruited in this study. All the patients were treated with intravenous drip of CPT-11 60 mg/m^2 and DDP 30mg/m^2 at the time of the first day and the eighth day. Treating for 28 was served as one cycle, and all the patients were treated for two weeks, and then the efficacy and adverse effect were evalualed. [ Results] All the patients finished two cycles of chems, and a total of 38 cycles of chems were used. The efficacy and adverse events were evaluated in all patients. The effective rate was 41.2%, no pa[ients presented complete recover） （CR）, 7 patients presented partly recovel） （41.2%）, two patients presented stable （11.8%）, and eight patients showed progress （47.1%）. The median survival time （MST） was 9.1 months. The main adverse events included myelosuppression, nausea, vomiting and dian＇hea. The incidence of grade III/IV neutropenia, thrombocytopenia, nausea, vomiting and diarrhea was 17.6%, 11.8%, 23.5%and 11.8%, respectively. [Con; clusion] Irinotecan in combination with eisplatin is effective, which only has some tolerable adverse events in treating patients with advanced or relapsed esophageal cancer. It is valuable for clinical practicing.

关 键 词：伊立替康 顺铂 晚期食管癌 联合化疗 

分 类 号：R735.1[医药卫生—肿瘤]